<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01539746</url>
  </required_header>
  <id_info>
    <org_study_id>SIMPLIFy TAVI Trial</org_study_id>
    <nct_id>NCT01539746</nct_id>
  </id_info>
  <brief_title>Transcatheter Aortic Valve Implantation Without Predilation</brief_title>
  <acronym>SIMPLIFy TAVI</acronym>
  <official_title>Use of the Self-Expanding Medtronic CoreValve Prosthesis Without Predilation in Patients With Severely IMPaired Left-VentrIcular Ejection Fraction for TAVI Trial - The SIMPLIFy TAVI Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Bonn</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Bonn</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to demonstrate that the avoidance of balloon valvuloplasty for
      predilation of the native aortic valve is associated with a reduction of the composite
      primary endpoint in TAVI patients with severely impaired left-ventricular ejection fraction
      (LVEF ≤35%).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Transcatheter aortic valve implantation (TAVI) has evolved as an alternative to surgical
      aortic valve replacement (SAVR) with now more than 50,000 implantations in patients with
      symptomatic severe aortic stenosis, who were considered to be at very high or prohibitive
      operative risk. Before deployment of transcatheter heart valves (THV), current medical
      practice requires right-ventricular rapid burst pacing (&gt;180 bpm) with induction of a
      functional cardiac arrest for up to 30 seconds for balloon aortic valvuloplasty (BAV). This
      step is thought to be necessary to predilate the native aortic valve and to facilitate an
      accurate positioning of the THV. However, BAV has been shown to have numerous detrimental
      effects: i) the functional cardiac arrest induced by rapid pacing for BAV leads to transient
      coronary, cerebral, and renal ischemia. ii) In patients with impaired left ventricular
      ejection fraction, prolonged cardiac depression after rapid pacing is observed and may result
      in hemodynamic failure and systemic inflammatory response syndrome (SIRS), which are both
      associated with a high peri-procedural mortality. iii) BAV has been identified as a major
      source of embolization of thrombotic and valvular material and increases the risk for
      coronary obstruction with subsequent myocardial infarction and stroke. iv) the local trauma
      in the left-ventricular outflow tract caused by BAV contributes to conduction disturbances
      with the need for permanent pacemaker implantation after TAVI.

      A non-randomized pilot study by Grube et al. (JACC Interventions 2011) has recently shown
      that TAVI without BAV is feasible and safe, since self-expanding THV are able to &quot;dilate&quot; the
      stenosed aortic valve through the radial forces of the self-expanding nitinol frame, in which
      the prosthesis is mounted. According to the mentioned study, omitting BAV allows the delivery
      of the THV in a controlled fashion without hemodynamic compromise of the patient.

      Patients with LVEF≤35% will be randomized (like the flip of a coin) to TAVI without BAV
      (experimental group) or TAVI with BAV for predilation (control group).
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary composite efficacy endpoint</measure>
    <time_frame>30 days after TAVI</time_frame>
    <description>Occurrence of all-cause mortality, stroke, non-fatal myocardial infarction, acute kidney injury, or pacemaker implantation at 30 days after TAVI.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular &amp; all-cause mortality</measure>
    <time_frame>6 months, 12 months after TAVI</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major/minor stroke</measure>
    <time_frame>6 months, 12 months after TAVI</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial infarction</measure>
    <time_frame>6 months, 12 months after TAVI</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>conduction disturbances and pacemaker implantation rate</measure>
    <time_frame>6 months, 12 months after TAVI</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute kidney injury</measure>
    <time_frame>6 months, 12 months after TAVI</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of postdilation</measure>
    <time_frame>30 days, 6 months, 12 months after TAVI</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transvalvular mean gradient as assessed by echocardiography</measure>
    <time_frame>30 days, 6 months, 12 months after TAVI</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Re-hospitalization for symptoms of cardiac/valve-related decompensation</measure>
    <time_frame>30 days, 6 months, 12 months after TAVI</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of periprosthetic aortic regurgitation (AR) as assessed by echocardiography, angiography, and hemodynamic measurements (AR index)</measure>
    <time_frame>30 days, 6 months, 12 months after TAVI</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Life-threatening/major/minor bleeding</measure>
    <time_frame>30 days, 6 months, 12 months after TAVI</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vascular access complications</measure>
    <time_frame>30 days, 6 months, 12 months after TAVI</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Repeat procedure for valve-related dysfunction (surgical or interventional therapy)</measure>
    <time_frame>30 days, 6 months, 12 months after TAVI</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">110</enrollment>
  <condition>Aortic Stenosis</condition>
  <condition>Left Ventricular Function Systolic Dysfunction</condition>
  <condition>High-risk Patients</condition>
  <condition>Transcatheter Aortic Valve Implantation</condition>
  <arm_group>
    <arm_group_label>TAVI without predilation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard TAVI procedure</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>TAVI without BAV</intervention_name>
    <description>Avoidance of balloon valvuloplasty (BAV) of the native aortic valve before valve deployment</description>
    <arm_group_label>TAVI without predilation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>TAVI standard procedure</intervention_name>
    <description>TAVI standard procedure including BAV before valve deployment</description>
    <arm_group_label>Standard TAVI procedure</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  LVEF ≤35%

          -  Aortic valve stenosis with an aortic valve area &lt;1 cm2 (&lt;0,6 cm3/m2)

          -  Males or females at least 18 years of age

          -  Logistic EuroSCORE ≥15% and age ≥75 years or if age &lt;75 years: logistic EuroSCORE ≥20%
             and/or a significant contraindication for open heart surgery (e.g., porcelain aorta or
             severe COPD)

          -  Signed informed consent

        Exclusion Criteria:

          -  Patients with a device regulating the heart rhythm by pacing (e.g. pacemaker,
             resynchronization device, implanted defibrillator)

          -  Patients with a pre-existing class I or class II indication for new pacemaker
             implantation according to the 2007 ESC guidelines

          -  Lack of written informed consent, severe mental disorder, drug/alcohol addiction

          -  Life expectancy &lt; 1 year

          -  Hypersensitivity or contraindication to acetyl salicyl acid, heparin, ticlopidine,
             clopidogrel, nitinol or sensitivity to contrast media that cannot be adequately
             premedicated

          -  Recent myocardial infarction (STEMI within the last 3 months)

          -  Left ventricular or atrial thrombus by echocardiography

          -  Uncontrolled atrial fibrillation

          -  Mitral or tricuspidal valvular insufficiency (&gt; grade II)

          -  Previous aortic valve replacement with mechanical valve

          -  Evolutive or recent cerebrovascular event (within the last 3 months)

          -  Vascular conditions that make insertion and endovascular access to the aortic valve
             impossible

          -  Symptomatic carotid or vertebral arterial narrowing (&gt;70%) disease

          -  Abdominal or thoracic aortic aneurysm in the path of the delivery system

          -  Bleeding diathesis or coagulopathy or patient refusing blood transfusion

          -  Active gastritis or peptic ulcer disease

          -  Severely impaired renal function, GFR &lt; 30 ml/min

          -  Participation in another drug or device study that would jeopardize the appropriate
             analysis of end-points of this study.

          -  High probability of non-adherence to the follow-up requirements (due to social,
             psychological or medical reasons)

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Georg Nickenig, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Medicine II, University Hospital Bonn</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jan-Malte Sinning, MD</last_name>
    <role>Study Director</role>
    <affiliation>Department of Medicine II, University Hospital Bonn</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jan-Malte Sinning, MD</last_name>
    <phone>+49-228-287-15507</phone>
    <email>jan-malte.sinning@ukb.uni-bonn.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Medicine II - Cardiology, University Hospital Bonn</name>
      <address>
        <city>Bonn</city>
        <zip>53105</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jan-Malte Sinning, MD</last_name>
    </contact>
    <investigator>
      <last_name>Georg Nickenig, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jan-Malte Sinning, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Cardiology, University Hospital Düsseldorf</name>
      <address>
        <city>Düsseldorf</city>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Malte Kelm, MD</last_name>
    </contact>
    <investigator>
      <last_name>Malte Kelm, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>West German Heart Center, University Hospital Essen</name>
      <address>
        <city>Essen</city>
        <zip>45122</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Raimund Erbel, MD</last_name>
    </contact>
    <investigator>
      <last_name>Raimund Erbel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Philipp Kahlert, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Medicine III - Cardiology, University Hospital Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hugo A Katus, MD</last_name>
    </contact>
    <investigator>
      <last_name>Hugo A Katus, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Raffi Bekeredjian, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Cardiology, Hospital Barmherzige Brüder Trier</name>
      <address>
        <city>Trier</city>
        <zip>54292</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Karl Eugen Hauptmann, MD</last_name>
    </contact>
    <investigator>
      <last_name>Karl Eugen Hauptmann, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Medicine III - Cardiology, University Hospital Tübingen</name>
      <address>
        <city>Tübingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Meinrad Gawaz, MD</last_name>
    </contact>
    <investigator>
      <last_name>Meinrad Gawaz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Grube E, Naber C, Abizaid A, Sousa E, Mendiz O, Lemos P, Kalil Filho R, Mangione J, Buellesfeld L. Feasibility of transcatheter aortic valve implantation without balloon pre-dilation: a pilot study. JACC Cardiovasc Interv. 2011 Jul;4(7):751-7. doi: 10.1016/j.jcin.2011.03.015.</citation>
    <PMID>21777882</PMID>
  </reference>
  <reference>
    <citation>Leon MB, Piazza N, Nikolsky E, Blackstone EH, Cutlip DE, Kappetein AP, Krucoff MW, Mack M, Mehran R, Miller C, Morel MA, Petersen J, Popma JJ, Takkenberg JJ, Vahanian A, van Es GA, Vranckx P, Webb JG, Windecker S, Serruys PW. Standardized endpoint definitions for Transcatheter Aortic Valve Implantation clinical trials: a consensus report from the Valve Academic Research Consortium. J Am Coll Cardiol. 2011 Jan 18;57(3):253-69. doi: 10.1016/j.jacc.2010.12.005. Epub 2011 Jan 7.</citation>
    <PMID>21216553</PMID>
  </reference>
  <reference>
    <citation>Leon MB, Smith CR, Mack M, Miller DC, Moses JW, Svensson LG, Tuzcu EM, Webb JG, Fontana GP, Makkar RR, Brown DL, Block PC, Guyton RA, Pichard AD, Bavaria JE, Herrmann HC, Douglas PS, Petersen JL, Akin JJ, Anderson WN, Wang D, Pocock S; PARTNER Trial Investigators. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. N Engl J Med. 2010 Oct 21;363(17):1597-607. doi: 10.1056/NEJMoa1008232. Epub 2010 Sep 22.</citation>
    <PMID>20961243</PMID>
  </reference>
  <reference>
    <citation>Sinning JM, Scheer AC, Adenauer V, Ghanem A, Hammerstingl C, Schueler R, Müller C, Vasa-Nicotera M, Grube E, Nickenig G, Werner N. Systemic inflammatory response syndrome predicts increased mortality in patients after transcatheter aortic valve implantation. Eur Heart J. 2012 Jun;33(12):1459-68. doi: 10.1093/eurheartj/ehs002. Epub 2012 Jan 26.</citation>
    <PMID>22285582</PMID>
  </reference>
  <reference>
    <citation>Nuis RJ, Van Mieghem NM, Schultz CJ, Tzikas A, Van der Boon RM, Maugenest AM, Cheng J, Piazza N, van Domburg RT, Serruys PW, de Jaegere PP. Timing and potential mechanisms of new conduction abnormalities during the implantation of the Medtronic CoreValve System in patients with aortic stenosis. Eur Heart J. 2011 Aug;32(16):2067-74. doi: 10.1093/eurheartj/ehr110. Epub 2011 May 28.</citation>
    <PMID>21622979</PMID>
  </reference>
  <reference>
    <citation>Kahlert P, Erbel R. Transcatheter aortic valve implantation in the era after commercialization: quo vadis in the real world? Circulation. 2011 Jan 25;123(3):239-41. doi: 10.1161/CIRCULATIONAHA.110.004713. Epub 2011 Jan 10.</citation>
    <PMID>21220739</PMID>
  </reference>
  <reference>
    <citation>Ghanem A, Müller A, Nähle CP, Kocurek J, Werner N, Hammerstingl C, Schild HH, Schwab JO, Mellert F, Fimmers R, Nickenig G, Thomas D. Risk and fate of cerebral embolism after transfemoral aortic valve implantation: a prospective pilot study with diffusion-weighted magnetic resonance imaging. J Am Coll Cardiol. 2010 Apr 6;55(14):1427-32. doi: 10.1016/j.jacc.2009.12.026. Epub 2010 Feb 24.</citation>
    <PMID>20188503</PMID>
  </reference>
  <reference>
    <citation>Drews T, Pasic M, Buz S, Unbehaun A, Dreysse S, Kukucka M, Mladenow A, Hetzer R. Transcranial Doppler sound detection of cerebral microembolism during transapical aortic valve implantation. Thorac Cardiovasc Surg. 2011 Jun;59(4):237-42. doi: 10.1055/s-0030-1250495. Epub 2011 Mar 25.</citation>
    <PMID>21442580</PMID>
  </reference>
  <reference>
    <citation>Sinning JM, Ghanem A, Steinhäuser H, Adenauer V, Hammerstingl C, Nickenig G, Werner N. Renal function as predictor of mortality in patients after percutaneous transcatheter aortic valve implantation. JACC Cardiovasc Interv. 2010 Nov;3(11):1141-9. doi: 10.1016/j.jcin.2010.09.009.</citation>
    <PMID>21087750</PMID>
  </reference>
  <verification_date>January 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 21, 2012</study_first_submitted>
  <study_first_submitted_qc>February 24, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 27, 2012</study_first_posted>
  <last_update_submitted>January 30, 2013</last_update_submitted>
  <last_update_submitted_qc>January 30, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 31, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Bonn</investigator_affiliation>
    <investigator_full_name>Georg Nickenig</investigator_full_name>
    <investigator_title>Director, Department of Medicine II</investigator_title>
  </responsible_party>
  <keyword>Aortic stenosis</keyword>
  <keyword>Transcatheter aortic valve implantation</keyword>
  <keyword>TAVI</keyword>
  <keyword>Predilation</keyword>
  <keyword>Balloon valvuloplasty</keyword>
  <keyword>BAV</keyword>
  <keyword>CoreValve</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aortic Valve Stenosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

